ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. November 21, 2019
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference Press release LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 13, 2017
ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 17, 2018
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. September 09, 2019
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Press release Key updates September 12, 2017
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares Press release LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 14, 2017
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. September 07, 2023
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 11, 2019
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness January 04, 2022
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates November 29, 2017